In This Article:
BALA CYNWYD, PA / ACCESSWIRE / September 19, 2019 / Brodsky & Smith, LLC reminds investors of the September 23, 2019 deadline to file to be a lead plaintiff regarding class action lawsuits against the following companies for violations of federal securities laws. If you purchased either of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.
L BRANDS, INC. (LB)
Shares purchased between May 31, 2018 and November 19, 2018
Deadline: September 23, 2019
According to the complaint, L Brands, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the Victoria’s Secret and PINK businesses were having a material adverse effect on the Company’s cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands’ then-current business operations and future financial prospects.
Additional information can be found at: http://www.brodskysmith.com/cases/l-brands-inc-nyse-lb/, or call: 877-534-2590. No cost or obligation.
KARYOPHARM THERAPEUTICS, INC. (KPTI)
Shares purchased between March 2, 2017 and February 22, 2019
Deadline: September 23, 2019
According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.